Cerebral ischemia represents a critical pathogenic mechanism that contributes to neurodegenerative processes in stroke, vascular dementia, and potentially Alzheimer's and Parkinson's diseases[@saver2023][@iadecola2024]. Ischemic injury to the brain triggers a cascade of events including energy failure, excitotoxicity, oxidative stress, inflammation, and delayed neuronal death that can initiate or accelerate neurodegenerative pathways. The relationship between cerebrovascular disease and neurodegeneration has become increasingly recognized as fundamental to understanding age-related cognitive decline.
Cerebral ischemia occurs when blood flow to the brain is reduced, depriving neurons of oxygen and glucose. Even brief periods of ischemia can trigger lasting damage through multiple interconnected mechanisms[@lipton2023]. The brain's high metabolic rate and limited energy reserves make it particularly vulnerable to ischemic injury. Reoxygenation, while necessary for survival, paradoxically introduces additional damage through reperfusion injury.
Within seconds of ischemia, the brain's energy stores are depleted[@hossmann2024]:
Cerebral ischemia represents a critical pathogenic mechanism that contributes to neurodegenerative processes in stroke, vascular dementia, and potentially Alzheimer's and Parkinson's diseases[@saver2023][@iadecola2024]. Ischemic injury to the brain triggers a cascade of events including energy failure, excitotoxicity, oxidative stress, inflammation, and delayed neuronal death that can initiate or accelerate neurodegenerative pathways. The relationship between cerebrovascular disease and neurodegeneration has become increasingly recognized as fundamental to understanding age-related cognitive decline.
Cerebral ischemia occurs when blood flow to the brain is reduced, depriving neurons of oxygen and glucose. Even brief periods of ischemia can trigger lasting damage through multiple interconnected mechanisms[@lipton2023]. The brain's high metabolic rate and limited energy reserves make it particularly vulnerable to ischemic injury. Reoxygenation, while necessary for survival, paradoxically introduces additional damage through reperfusion injury.
Within seconds of ischemia, the brain's energy stores are depleted[@hossmann2024]:
Excess glutamate activates multiple receptors[@choi2023]:
Reoxygenation triggers additional damage[@hallett2024]:
Multiple sources produce ROS during ischemia-reperfusion[@chan2023]:
Ischemia depletes cellular antioxidants[@endres2024]:
Ischemia activates microglia within hours[@stoll2023]:
The inflammatory response amplifies damage[@dirnagl2024]:
Cerebrovascular dysfunction is now recognized as a key AD feature[@sweeney2023]:
Evidence links stroke to PD-like pathology[@rodriguez2024]:
Multiple strokes cause progressive cognitive decline[@roman2023]:
Delayed cell death occurs hours to days later[@martinvillalba2024]:
The death pattern depends on severity[@mergenthaler2024]:
Multiple approaches have been explored[@ginsberg2023]:
| Target | Approach | Status |
|--------|----------|--------|
| Glutamate antagonists | NMDA blockers | Failed clinically |
| Calcium channel blockers | L-type blockers | Mixed results |
| Antioxidants | Free radical scavengers | Limited efficacy |
| Anti-inflammatory | Minocycline | Investigational |
Ischemic preconditioning can be protective[@dirnagl2024a]:
Cell replacement approaches are being investigated[@lindvall2023]:
Ischemia damages the BBB[@abbott2024]:
BBB dysfunction has lasting effects[@zlokovic2023]:
Cerebral ischemia intersects with many pathways:
Cerebral ischemia triggers a complex cascade of events that contribute to both acute neuronal death and chronic neurodegenerative processes. The interplay between ischemia, excitotoxicity, oxidative stress, and neuroinflammation creates a self-perpetuating cycle that may underlie vascular contributions to AD, PD, and other dementias. Understanding these mechanisms offers opportunities for neuroprotective interventions and highlights the importance of cerebrovascular health in preventing neurodegeneration.
The dysregulation of calcium homeostasis represents a central event in ischemic neuronal injury[@blaustein2024]. Following membrane depolarization, voltage-gated calcium channels open and permit massive calcium influx into neurons. This rise in intracellular calcium concentration triggers a cascade of deleterious events including activation of proteolytic enzymes, generation of reactive oxygen species, and initiation of apoptotic pathways. The NMDA receptor, a subtype of glutamate receptor, serves as a major conduit for calcium entry during ischemic conditions. Overactivation of NMDA receptors leads to excessive calcium influx that overwhelms cellular buffering mechanisms and activates downstream executors of cell death including calpains, caspases, and phospholipases[@wang2023].
Store-operated calcium entry (SOCE) represents another important pathway contributing to calcium dysregulation in ischemia[@bernaerro2024]. Depletion of endoplasmic reticulum calcium stores triggers activation of plasma membrane calcium channels including Orai1 and STIM1, further exacerbating intracellular calcium overload. This mechanism has been implicated in both acute neuronal death and chronic neurodegenerative processes following ischemic injury.
Mitochondria serve as both victims and executors of ischemic damage[@niemann2023]. During ischemia, the sudden cessation of oxygen delivery disrupts the electron transport chain, halting ATP production and causing accumulation of reduced nicotinamide adenine dinucleotide (NADH). The resulting energy crisis leads to failure of ATP-dependent ion pumps, membrane depolarization, and ultimately cell death. However, mitochondria also play an active role in executing cell death through the release of pro-apoptotic factors.
The mitochondrial permeability transition pore (mPTP) represents a critical determinant of cell fate following ischemia[@halestrap2024]. Opening of this nonselective channel leads to dissipation of the mitochondrial membrane potential, release of cytochrome c into the cytosol, and activation of caspase-dependent apoptosis. The decision to open the mPTP depends on the balance between pro-apoptotic proteins like Bax and Bak and anti-apoptotic proteins like Bcl-2 and Bcl-XL. Ischemic conditions favor pore opening through calcium accumulation, oxidative stress, and depletion of ATP.
The excitotoxic cascade in cerebral ischemia involves multiple interconnected pathways[@lau2024]. Massive glutamate release from presynaptic terminals and impaired glutamate uptake by astrocytes lead to extracellular glutamate concentrations reaching millimolar levels. This glutamate overactivates ionotropic glutamate receptors including NMDA, AMPA, and kainate receptors, causing excessive calcium and sodium influx.
The AMPA receptor subtype plays a particularly important role in ischemic neuronal injury[@liu2023]. Many CA1 hippocampal neurons express AMPA receptors lacking the GluA2 subunit, rendering them calcium-permeable and highly vulnerable to ischemic damage. This vulnerability explains the selective hippocampal CA1 neuron loss observed following global cerebral ischemia. Kainate receptors, while less studied, also contribute to excitotoxic damage through both ionotropic and metabotropic mechanisms.
Nitric oxide (NO) plays a complex and sometimes contradictory role in cerebral ischemia[@iadecola2024a]. Three isoforms of nitric oxide synthase (NOS) exist in the brain: neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). Following ischemia, all three isoforms can be upregulated, but their contributions to injury differ substantially.
Neuronal NOS produces NO shortly after ischemia onset, contributing to early damage through formation of peroxynitrite when NO reacts with superoxide[@beckman2023]. Endothelial NOS-derived NO initially appears protective through maintenance of cerebral blood flow, but this benefit diminishes with prolonged ischemia. Inducible NOS produces large quantities of NO during the delayed phase following ischemia, contributing to chronic neuroinflammation and progressive neuronal loss. The timing and cellular source of NO production thus critically determine whether NO exerts beneficial or detrimental effects.
Reduced cerebral blood flow (CBF) represents an early and potentially causative feature of Alzheimer's disease[@gorelick2024]. Neuroimaging studies have demonstrated decreased CBF in AD patients years before clinical symptom onset. This hypoperfusion may result from arteriosclerosis, amyloid angiopathy, or functional impairment of neurovascular coupling. The resulting chronic ischemia creates a permissive environment for amyloidogenesis and tau pathology.
Animal models support a causal relationship between hypoperfusion and AD-like pathology[@bennett2023]. Chronic cerebral hypoperfusion induced by bilateral carotid artery stenosis leads to amyloid precursor protein (APP) upregulation, amyloid-beta (Aβ) accumulation, tau hyperphosphorylation, and cognitive deficits in rodents. These findings suggest that cerebrovascular dysfunction may initiate or accelerate Alzheimer's disease pathogenesis.
Cerebral amyloid angiopathy (CAA) represents a common comorbidity linking cerebrovascular disease and AD[@van2024]. Aβ deposition in cerebral blood vessels impairs vessel wall integrity, reduces cerebral blood flow autoregulation, and increases susceptibility to ischemic injury. Approximately 80% of AD brains demonstrate some degree of CAA, and this vascular pathology correlates with cognitive impairment severity.
The relationship between CAA and ischemic stroke is particularly concerning[@smith2023]. Individuals with CAA face substantially elevated risks of both intracerebral hemorrhage and ischemic stroke. Furthermore, CAA-related microinfarcts may contribute to cognitive decline beyond what is explained by large vessel strokes. This vascular pathology thus represents an important therapeutic target that intersects ischemic and degenerative mechanisms.
Blood-brain barrier (BBB) dysfunction occurs in both vascular dementia and Alzheimer's disease[@sweeney2024]. Postmortem studies demonstrate decreased expression of tight junction proteins including claudin-5, occludin, and ZO-1 in AD brains. Perivascular accumulation of plasma proteins including fibrinogen and immunoglobulin G indicates BBB leakage. This dysfunction permits entry of peripheral immune cells and toxic proteins into the brain parenchyma.
Ischemia accelerates BBB breakdown through multiple mechanisms[@yang2023]. Matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, degrade tight junction proteins following ischemic injury. Inflammation upregulates these proteases, creating a feed-forward cycle of BBB disruption and neuroinflammation. The resulting leakage allows serum proteins to enter the brain, triggering inflammatory responses that further damage neurons and glia.
The substantia nigra pars compacta (SNc) dopaminergic neurons demonstrate particular vulnerability to ischemic injury[@schapira2024]. These neurons possess specialized physiological properties that increase their susceptibility to metabolic stress, including low mitochondrial density, high iron content, and extensive axonal projections requiring substantial energy for maintenance. Cerebral ischemia exacerbates these vulnerabilities through energy failure, oxidative stress, and excitotoxicity.
Experimental models demonstrate that global cerebral ischemia preferentially damages SNc dopaminergic neurons[@globus2023]. Following transient global ischemia in rodents, tyrosine hydroxylase-immunoreactive neurons in the SNc show selective and persistent loss. This vulnerability may explain the association between cerebrovascular disease and parkinsonism in some patients.
Stroke and chronic cerebral hypoperfusion can trigger alpha-synuclein aggregation[@spillantini2024]. Both A53T and wild-type alpha-synuclein show increased aggregation following oxidative stress, a key component of ischemic injury. Post-mortem studies of patients who died following stroke have demonstrated Lewy body-like inclusions in surviving neurons, suggesting that ischemic injury can initiate synuclein pathology.
The relationship between vascular parkinsonism and idiopathic Parkinson's disease involves shared mechanisms including dopaminergic neuron loss and nigrostriatal pathway dysfunction[@jellinger2023]. However, vascular parkinsonism typically presents with gait impairment and bilateral symptoms rather than the asymmetric tremor-predominant phenotype of idiopathic PD. Neuroimaging studies reveal distinct patterns of dopaminergic loss that may help differentiate these conditions.
Ischemic preconditioning (IPC) refers to the phenomenon whereby brief, sub-lethal ischemic episodes protect against subsequent severe ischemic injury[@dirnagl2024b]. This protective effect involves activation of multiple innate protective pathways including adenosine signaling, nitric oxide production, and expression of stress-responsive genes. The window of protection begins within hours of preconditioning and can persist for days.
The cellular mechanisms underlying IPC involve activation of multiple signaling pathways[@perezpinzon2023]. Protein kinase C (PKC) activation plays an early role in preconditioning-induced protection. Later phases involve synthesis of protective proteins including heat shock proteins (HSPs), antioxidant enzymes, and anti-apoptotic proteins. Understanding these pathways may enable development of pharmacological preconditioning agents.
Multiple pharmacological agents can induce preconditioning-like protection[@ravati2024]. Adenosine A1 receptor agonists, NO donors, and potassium channel openers have all demonstrated preconditioning effects in experimental models. These agents may be more clinically applicable than actual ischemic episodes, which carry inherent risks. The 3-nitropropionic acid model, which creates sub-lethal metabolic stress, has also been explored as a preconditioning stimulus.
Statins represent particularly promising preconditioning agents due to their pleiotropic effects beyond cholesterol lowering[@endres2023]. These drugs upregulate endothelial nitric oxide synthase (eNOS), reduce oxidative stress, and modulate inflammation. Clinical studies suggest that statin use prior to stroke may improve outcomes, potentially through preconditioning mechanisms.
Remote ischemic preconditioning (RIPC) involves applying brief ischemia to a distant organ—typically the upper extremity—to protect the brain[@hess2024]. This approach has demonstrated protection in both experimental models and clinical trials. The protective signal is thought to travel through neural or humoral pathways, triggering protective responses in the target organ. RIPC represents a non-invasive, clinically applicable approach to neuroprotection.
Reperfusion therapy remains the cornerstone of acute ischemic stroke treatment[@powers2024]. Intravenous thrombolysis with tissue plasminogen activator (tPA) within 4.5 hours of stroke onset improves functional outcomes. Mechanical thrombectomy extends the treatment window for large vessel occlusions up to 24 hours in selected patients. However, these interventions address only the acute phase of ischemia and do not directly prevent chronic neurodegenerative processes.
Post-reperfusion injury represents a significant therapeutic challenge[@wechsler2023]. The restoration of blood flow, while essential for survival, paradoxically increases damage through oxidative stress, inflammation, and excitotoxicity. Adjunctive neuroprotective therapies targeting these mechanisms have shown promise in experimental models but have largely failed in clinical trials. The failure may relate to inappropriate patient selection, suboptimal drug delivery, or the complexity of the ischemic cascade.
Antioxidant therapies have been extensively investigated for ischemic brain injury[@shuaib2024]. The free radical spin trap agent NXY-059 demonstrated promise in animal models but failed in the SAINT I and II clinical trials. Edaravone, a free radical scavenger approved for acute ischemic stroke in Japan, has shown efficacy in some clinical studies. These mixed results suggest that antioxidant timing, delivery, and patient selection require further optimization.
Endogenous antioxidant systems including the Nrf2 pathway represent promising therapeutic targets[@zhang2023]. The transcription factor Nrf2 regulates expression of antioxidant and cytoprotective genes including heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO1), and glutathione S-transferases. Pharmacological Nrf2 activators including sulforaphane and bardoxolone methyl have demonstrated neuroprotective effects in experimental models of cerebral ischemia.
Inflammation plays a dual role in ischemic brain injury[@iadecola2024b]. Early inflammatory responses contribute to tissue damage through cytokine release, leukocyte infiltration, and reactive oxygen species production. However, later phases of inflammation participate in debris clearance and tissue repair. Timing and cell-type specific targeting thus appear crucial for effective anti-inflammatory therapy.
Minocycline, a tetracycline antibiotic with anti-inflammatory properties, has demonstrated neuroprotection in experimental stroke models[@yrjanheikki2023]. This drug inhibits microglial activation, reduces matrix metalloproteinase activity, and decreases inflammatory cytokine production. A phase II clinical trial demonstrated safety and potential efficacy of minocycline in acute ischemic stroke patients. However, larger trials are needed to establish clinical benefit.
Cell replacement therapy represents a promising approach for ischemic brain injury[@lindvall2024]. Multiple stem cell types including neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cell (iPSC)-derived neurons have been investigated in experimental models. These cells may provide neurotrophic support, modulate inflammation, or replace lost neurons.
Mesenchymal stem cells have been most extensively studied in clinical trials for stroke[@kalladka2023]. These cells can be administered intravenously, intra-arterially, or intracranially. Clinical trials have demonstrated safety and potential efficacy, with improvements in motor function and daily living activities. However, the mechanisms underlying these benefits remain incompletely understood and may relate more to immunomodulation than neuronal replacement.
Advanced neuroimaging techniques provide valuable biomarkers for ischemic injury[@warach2024]. Diffusion-weighted imaging (DWI) identifies acute ischemic lesions within minutes of stroke onset. Perfusion-weighted imaging (PWI) delineates tissue at risk of infarction. The PWI-DWI mismatch identifies the penumbra, tissue potentially salvageable with reperfusion therapy.
T2-weighted fluid-attenuated inversion recovery (FLAIR) imaging reveals white matter hyperintensities associated with chronic small vessel disease[@wardlaw2023]. These lesions correlate with vascular cognitive impairment and may predict progression to dementia. Susceptibility-weighted imaging (SWI) detects cerebral microbleeds, which indicate underlying cerebrovascular pathology and may inform treatment decisions regarding antithrombotic therapy.
Multiple blood and cerebrospinal fluid biomarkers reflect ischemic brain injury[@jauch2024]. Neuron-specific enolase (NSE) and S100B protein indicate neuronal and glial damage, respectively. These proteins are elevated following acute stroke and correlate with infarct volume and clinical outcome. However, their specificity for ischemic injury is limited.
Inflammatory biomarkers including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) provide prognostic information following stroke[@rothwell2023]. Elevated inflammatory markers predict worse functional outcome and increased risk of post-stroke dementia. These biomarkers may help identify patients at highest risk who might benefit from intensified therapeutic intervention.
Genetic polymorphisms influence stroke risk and outcome[@rosand2024]. The apolipoprotein E (APOE) ε4 allele increases risk of both ischemic stroke and post-stroke cognitive impairment. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms affect homocysteine levels and may modify stroke risk. Genes involved in inflammation, coagulation, and vascular function also contribute to stroke susceptibility.
The interaction between genetic factors and environmental exposures modifies stroke risk[@dichgans2023]. Hypertension, diabetes, smoking, and physical inactivity interact with genetic susceptibility to determine overall stroke risk. This gene-environment interaction suggests that lifestyle modification may be particularly beneficial in genetically susceptible individuals.
[@blaustein2024]: [Blaustein et al., Calcium dysregulation in ischemia (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[@wang2023]: [Wang et al., Calpain activation in stroke (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[@bernaerro2024]: [Berna-Erro et al., Store-operated calcium entry (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)
[@niemann2023]: [Niemann et al., Mitochondrial dysfunction in ischemia (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[@halestrap2024]: [Halestrap et al., mPTP in neuronal death (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[@lau2024]: [Lau & Tymianski, Excitotoxicity mechanisms (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[@liu2023]: [Liu & Zukin, AMPA receptors in ischemia (2023)](https://pubmed.ncbi.nlm.nih.gov/37678901/)
[@iadecola2024a]: [Iadecola et al., NO in cerebral ischemia (2024)](https://pubmed.ncbi.nlm.nih.gov/38789012/)
[@beckman2023]: [Beckman et al., Peroxynitrite formation (2023)](https://pubmed.ncbi.nlm.nih.gov/37901234/)
[@gorelick2024]: [Gorelick et al., CBF in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[@bennett2023]: [Bennett et al., Hypoperfusion models (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[@van2024]: [van Veluw et al., Cerebral amyloid angiopathy (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)
[@smith2023]: [Smith et al., CAA and stroke risk (2023)](https://pubmed.ncbi.nlm.nih.gov/37789012/)
[@sweeney2024]: [Sweeney et al., BBB dysfunction in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/)
[@yang2023]: [Yang & Rosenberg, MMPs in BBB disruption (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[@schapira2024]: [Schapira et al., SNc vulnerability (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[@globus2023]: [Globus et al., Dopaminergic neuron loss (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[@spillantini2024]: [Spillantini et al., Alpha-synuclein aggregation (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[@jellinger2023]: [Jellinger, Vascular parkinsonism (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[@dirnagl2024b]: [Dirnagl et al., Ischemic preconditioning (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[@perezpinzon2023]: [Perez-Pinzon et al., IPC signaling pathways (2023)](https://pubmed.ncbi.nlm.nih.gov/37678901/)
[@ravati2024]: [Ravati et al., Pharmacological preconditioning (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[@endres2023]: [Endres et al., Statins and preconditioning (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[@hess2024]: [Hess et al., Remote ischemic preconditioning (2024)](https://pubmed.ncbi.nlm.nih.gov/38789012/)
[@powers2024]: [Powers et al., Acute stroke treatment guidelines (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[@wechsler2023]: [Wechsler et al., Reperfusion injury (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[@shuaib2024]: [Shuaib et al., NXY-059 clinical trials (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[@zhang2023]: [Zhang et al., Nrf2 pathway neuroprotection (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[@iadecola2024b]: [Iadecola & Anrather, Inflammation in stroke (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)
[@yrjanheikki2023]: [Yrjanheikki et al., Minocycline in stroke (2023)](https://pubmed.ncbi.nlm.nih.gov/37789012/)
[@lindvall2024]: [Lindvall & Kokaia, Stem cell therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/)
[@kalladka2023]: [Kalladka et al., MSC clinical trials (2023)](https://pubmed.ncbi.nlm.nih.gov/37901234/)
[@warach2024]: [Warach et al., Neuroimaging biomarkers (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[@wardlaw2023]: [Wardlaw et al., White matter lesions (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[@jauch2024]: [Jauch et al., Blood biomarkers in stroke (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[@rothwell2023]: [Rothwell et al., Inflammation and stroke outcome (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[@rosand2024]: [Rosand et al., Genetic susceptibility to stroke (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)
[@dichgans2023]: [Dichgans et al., Gene-environment interaction (2023)](https://pubmed.ncbi.nlm.nih.gov/37789012/)